Rebound insomnia. A potential hazard following withdrawal of certain benzodiazepines.
Five benzodiazepine drugs (diazepam, flunitrazepam, flurazepam hydrochloride, nitrazepam, and triazolam) were evaluated separately in 15 sleep laboratory studies. Rebound insomnia, a worsening of sleep compared with baseline, occurred following withdrawal of triazolam, nitrazepam, and flunitrazepam after they had been given in only single, nightly doses for short periods. The rebound insomnia was attributed to the short and intermediate half-lives of these drugs. Diazepam and flurazepam, which have longer half-lives, did not cause rebound insomnia on withdrawal. Rebound insomnia may play a role in the development of hypnotic drug dependence with shorter-acting benzodiazepine drugs.
D000208:Acute Disease; D001569:Benzodiazepines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005445:Flunitrazepam / Q000009:adverse effects; D006207:Half-Life; D006801:Humans; D009567:Nitrazepam / Q000009:adverse effects; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced* / Q000188:drug therapy; D013375:Substance Withdrawal Syndrome; D014229:Triazolam / Q000009:adverse effects
D001569:Benzodiazepines; D014229:Triazolam; D005445:Flunitrazepam; D009567:Nitrazepam